Shares of Sophiris Bio, Inc. (NASDAQ:SPHS) have received an average recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $6.60.

Several equities research analysts have recently weighed in on SPHS shares. HC Wainwright set a $6.00 target price on Sophiris Bio and gave the stock a “buy” rating in a research report on Saturday, June 10th. Maxim Group set a $6.00 price target on Sophiris Bio and gave the company a “buy” rating in a report on Thursday, June 8th. Rodman & Renshaw reaffirmed a “buy” rating and set a $6.00 target price on shares of Sophiris Bio in a report on Thursday, June 1st. Finally, ValuEngine downgraded Sophiris Bio from a “hold” rating to a “sell” rating in a report on Tuesday, June 13th.

A hedge fund recently raised its stake in Sophiris Bio stock. Vanguard Group Inc. boosted its stake in Sophiris Bio, Inc. (NASDAQ:SPHS) by 1.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 731,437 shares of the biopharmaceutical company’s stock after buying an additional 7,600 shares during the period. Vanguard Group Inc. owned 2.43% of Sophiris Bio worth $1,609,000 at the end of the most recent reporting period. Institutional investors own 5.50% of the company’s stock.

Sophiris Bio (SPHS) traded up 1.09% during trading on Tuesday, hitting $1.85. The stock had a trading volume of 116,034 shares. The stock’s 50-day moving average is $2.06 and its 200 day moving average is $2.44. Sophiris Bio has a one year low of $1.80 and a one year high of $6.13. The firm’s market cap is $55.71 million.

Sophiris Bio (NASDAQ:SPHS) last announced its quarterly earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.09) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.09). Equities analysts anticipate that Sophiris Bio will post ($0.39) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/15/sophiris-bio-inc-sphs-given-average-rating-of-buy-by-brokerages.html.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Analyst Recommendations for Sophiris Bio (NASDAQ:SPHS)

Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.